Organon (OGN) shares were advancing nearly 1% in recent Thursday trading after the company posted its Q3 revenue ahead of consensus.

The company reported Q3 non-GAAP net income Thursday of $0.87 per diluted share, unchanged from a year earlier.

Analysts polled by Capital IQ expected $0.90.

Revenue for the quarter ended Sept. 30 rose to $1.58 billion from $1.52 billion a year earlier.

Analysts expected $1.56 billion.

For 2024, the women's health company is projecting revenue of $6.38 billion from $6.43 billion compared with its prior forecast range of $6.25 billion to $6.45 billion.

Analysts are looking for $6.39 billion.

Organon said its board declared a quarterly dividend of $0.28, payable Dec. 12 to stockholders of record on Nov. 12.

As of Sept. 30, Organon had cash and cash equivalents of $763 million.

Price: 18.10, Change: +0.17, Percent Change: +0.95